
    
      Subjects reside in the clinical research unit for 3 periods of 11 days each, with a washout
      period of at least 7 days between treatment periods. . Each subject is treated with multiple
      oral doses of the IR formulation (b.i.d.) under fasted conditions and, OCAS-F, OCAS-M or
      OCAS-S formulation (q.d.) under fasted and fed conditions (high fat breakfast).

      The study is completed with a post-study visit between 7 and 14 days after discharge of
      period 3.
    
  